У нас вы можете посмотреть бесплатно A Paradigm Shift in Preventing Drug Resistant Epilepsy или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
                        Если кнопки скачивания не
                            загрузились
                            НАЖМИТЕ ЗДЕСЬ или обновите страницу
                        
                        Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
                        страницы. 
                        Спасибо за использование сервиса ClipSaver.ru
                    
Epilepsy, a chronic neurologic disorder, affects over 70 million patients globally. Despite the over 20 available antiseizure drugs for symptomatic treatment of epileptic seizures, about one-third of patients have seizures refractory to pharmacotherapy. Patients with this type of drug-resistant epilepsy have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life. Thus, early detection of drug-resistant epilepsy is crucial in order to establish potential treatment alternatives and determine if epilepsy surgery is the right treatment choice. At the 2023 American Epilepsy Society Annual Meeting, held December 1-5, in Orlando, Florida,SK Life Science is hosting a symposium titled “Impact of Continued Seizures and Strategies for Seizure Reduction/Freedom” that will be led by experts in the field.3 The company noted that the symposium will discuss currently available strategies for reducing and achieving seizure freedom, and the need to better understand patient goals for achieving seizure freedom and the impact of continued seizures on patients. Additionally, experts will speak on evidence-based treatment adjustments before patients consider surgery and the various treatment options available to support them in their epilepsy journey. Prior to the upcoming symposium, one of the speakers, Pavel Klein, MD, director of the Mid-Atlantic Epilepsy & Sleep Center and adjunct associate professor of neurology at George Washington University, sat downto provide an overview of the planned presentation. He spoke about how the advancements in genetic understanding and seizure detection technologies are potentially transforming epilepsy research and treatment. He also talked about the limitations faced by the one-third of Americans with epilepsy who don't respond to medications, and how the treatment landscape has evolved over the decades. Furthermore, Klein explained how early intervention using effective treatments can potentially suppress or prevent drug-resistant epilepsy, and the indicators that can help identify patients on this path. (https://www.neurologylive.com/view/pa...) More AES Content: -http://www.neurologylive.com/conferen...